Le scrutin présidentiel US reste incertain, mais le momentum semble être du côté de Donald Trump depuis début octobre : le candidat est désormais en tête dans 6 des 7 swing states, vient de dépasser Kamala Harris dans le vote national et est donné gagnant à 63% chez les parieurs. Nous rappelons les valeurs européennes à privilégier ou à éviter en cas de victoire de Donald Trump, et avons également listé les valeurs européennes ayant une base de production aux US, par nature moins expo...
The outcome of the US presidential election hangs in the balance, but the momentum seems to be with Donald Trump since the beginning of October: the candidate is now in the lead in six of the seven swing states, has just overtaken Kamala Harris in the national vote while 63% of punters are tipping him to win. We recap in the present note on the European stocks to play or avoid in the event of Donald Trump's victory and have also listed European stocks with a production base in the US,...
>Results broadly in line with estimates. Growth excluding regulatory effects - Results were in line with our estimates (-0.6% at EBITDA, -2% vs consensus) marked by the end of the regulatory useful life of the pre-1998 assets with an estimated impact of € 260m in 2024 (€ 187m impact in 9M 2024). Excluding this effect, revenues grew by +1.9%. Domestic electricity transmission accounted for 76% of revenues and 71% of EBITDA in 9M 2024 with sales and EBITDA declining by,...
We hosted our 4th ODDO BHF Iberian Forum on the 1st and 2nd of October 2024, virtually. In total, 63 companies were present. In the following note, we provide some initial feedback from the companies on day 2. - >ACS (=): good operating momentum maintained, Abertis and its dividends on the front page - Atresmedia (=): Q3 should be challenging but outlook reiterated - Befesa (=): zinc prices held up well, offsetting the negative impact of maintenance on Q3 volumes - CaixaBank ...
>H1 results aligned with FY 24 guidance - Decent set of results, slightly above our estimates (+2% in Q2 24 EBITDA), which reflect the end of the regulatory life of pre-1998 assets (with an estimated annual impact in revenues of € 260m: H1 24 Sales decline by -11.5%) and well positioned to meet the group’s annual guidance (EBITDA H1 24 of € 681m, -13.7% y-o-y, vs FY 24 guidance of > € 1.3bn and net profit H1 24e of € 269m, -24% y-o-y, vs FY 24 guidance). As we expecte...
We are removing GALP from our ODDO BHF European Large Caps list. The stock has chalked up a performance of +31.3% since its inclusion in the list on 20 March. Our analyst is adopting today a Neutral recommendation (vs Outperform) on the stock. - ...
>Results in line with estimates, adequate progress towards FY guidance - Results in line with our estimates marked by the loss of pre-1998 regulated assets (end of the useful remunerative life of the pre-98 assets with a FY impact estimated at € 260m in 2024) as widely anticipated. Domestic electricity infrastructure accounted for 76% of total revenues and 70% of total EBITDA recording a decline of 16% and 22% compared to last year levels in each category, fully expla...
>Regulatory impact drives results decline - Redeia will release Q1 2024 results on 30 April. Results are marked by the loss of pre-1998 regulated assets (estimated annual impact of € 260m in 2024: € 307m remuneration impact, partially offset by € 47m revenues from the start of extension of useful life of those assets) as widely anticipated by the company and consensus estimates. As a result, domestic electricity infrastructure is expected to reduce its contribution to...
L’année 2024 sera marquée par l’élection présidentielle américaine et l’annonce des rabais pour les 10 médicaments dont les prix sont dorénavant négociés directement par Medicare dans le cadre de l’IRA. Nous tablons sur une croissance des BPA 24e de 8% et relevons nos OC de 1% en moyenne. Nous privilégions GSK (Surperformance) qui allie valorisation attractive, croissance et newsflow. Nous maintenons notre recommandation Surperformance sur Sanofi qui devrait bénéficier d’un catalyseur...
2024 is set to be marked by the US presidential election and the announcement of rebates for the 10 drugs for which prices are now negotiated directly through Medicare under the IRA. We forecast EPS 24e growth of 8% and lift our target prices by 1% on average. We prefer GSK (Outperform) which combines an attractive valuation, growth and clinical newsflow. We maintain our Outperform rating on Sanofi which should benefit from a transformative clinical catalyst in H1. We lower our rating...
>Fine-tuning estimates following the 2024 guidance release - We are updating our estimates on Redeia following the annual accounts publication and the release of the 2024 guidance consisting of EBITDA above € 1.3bn and net profit of around € 500m. These references are 9% and 12% below our previous estimates respectively, which considered an EBITDA margin of 72% at the domestic electricity infrastructure business for 2024 and 71% in 2025, and we are now lowering this ...
Double materiality, climate transition plan, the value chain: the CSDR is set to revolutionise ESG reporting as of 2025. It should accelerate the sustainable transformation of the most committed companies and act as a weapon against greenwashing for the most reticent. The audit requirements guarantee a level of quality for data, but it will take several years before investors begin to reap all of the benefits. - ...
Double matérialité, transition climat, chaîne de valeur : la CSRD va révolutionner le reporting ESG, dès 2025. Elle devrait accélérer la transformation des entreprises les plus engagées et servir d’arme anti-greenwashing à l’encontre des plus réticentes. Les exigences d’audit garantissent une certaine qualité des données, mais il faudra patienter quelques années pour que les investisseurs en tirent tous les bénéfices. - ...
>Results in line with estimates, net profit beat on lower taxes and financing costs - Redeia FY 2023 results were broadly in line with our estimates at the operating level and somewhat above at the net profit level considering lower tax rate (20.9% vs 22.5%e and 21.7% in 2022) and better financial results. Results were supported by the contribution of International Infrastructure activities (consolidation of Argo in Brazil and good performance of TEN in Chile) and res...
3 valeurs sortent aujourd’hui de notre liste de Convictions Large Caps européennes. Nous prenons nos profits sur ASML (+ 30% depuis son entrée dans la liste) après sa forte hausse post publication de son T4 2023. Inversement, nous coupons notre position sur RWE (-15% depuis son entrée) après de bons résultats 2023 mais une guidance 2024 revue en baisse. Nous conservons Sodexo dans son nouveau périmètre mais sortons Pluxee. - ...
We are removing three stocks from the ODDO BHF European Large Caps Convictions List today. We are taking our profits on ASML (+30% since its inclusion in the list) after its strong gains since the publication of its Q4 2023 results. Conversely, we are reducing our position on RWE (-15% since its inclusion in the list) following a good set of 2023 results but a downward revision to 2024 guidance. We maintain Sodexo in its new scope in the list but withdraw Pluxee - ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.